Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer.

Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y, Wang J, Gadaleta E, Chelala C, Moore KM, Marshall JF, Chupin J, Schmid P, Jones JL, Lockley M, Cutillas PR, Grose RP.

Cell Rep. 2018 Feb 27;22(9):2469-2481. doi: 10.1016/j.celrep.2018.02.028.

2.

A 3D in vitro model of the human breast duct: a method to unravel myoepithelial-luminal interactions in the progression of breast cancer.

Carter EP, Gopsill JA, Gomm JJ, Jones JL, Grose RP.

Breast Cancer Res. 2017 Apr 21;19(1):50. doi: 10.1186/s13058-017-0843-4.

3.

Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.

Dawkins JB, Wang J, Maniati E, Heward JA, Koniali L, Kocher HM, Martin SA, Chelala C, Balkwill FR, Fitzgibbon J, Grose RP.

Cancer Res. 2016 Aug 15;76(16):4861-71. doi: 10.1158/0008-5472.CAN-16-0481. Epub 2016 Jun 8.

4.

Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.

Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM.

J Pathol. 2016 Jul;239(3):286-96. doi: 10.1002/path.4727. Epub 2016 May 25.

5.

Dysregulated FGF signalling in neoplastic disorders.

Tanner Y, Grose RP.

Semin Cell Dev Biol. 2016 May;53:126-35. doi: 10.1016/j.semcdb.2015.10.012. Epub 2015 Oct 19. Review.

PMID:
26463732
6.

Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction.

Carter EP, Fearon AE, Grose RP.

Trends Cell Biol. 2015 Apr;25(4):221-33. doi: 10.1016/j.tcb.2014.11.003. Epub 2014 Nov 29. Review.

PMID:
25467007
7.

Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation.

Coleman SJ, Watt J, Arumugam P, Solaini L, Carapuca E, Ghallab M, Grose RP, Kocher HM.

World J Gastroenterol. 2014 Jul 14;20(26):8471-81. doi: 10.3748/wjg.v20.i26.8471. Review.

8.

The ins and outs of fibroblast growth factor receptor signalling.

Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP.

Clin Sci (Lond). 2014 Aug;127(4):217-31. doi: 10.1042/CS20140100. Review.

PMID:
24780002
9.

Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion.

Coleman SJ, Chioni AM, Ghallab M, Anderson RK, Lemoine NR, Kocher HM, Grose RP.

EMBO Mol Med. 2014 Apr;6(4):467-81. doi: 10.1002/emmm.201302698. Epub 2014 Feb 6.

10.

Grb-ing receptor activation by the tail.

Fearon AE, Grose RP.

Nat Struct Mol Biol. 2014 Feb;21(2):113-4. doi: 10.1038/nsmb.2767. No abstract available.

PMID:
24500424
11.

Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.

Coleman SJ, Grose RP, Kocher HM.

J Hepatocell Carcinoma. 2014 May 29;1:43-54. doi: 10.2147/JHC.S48958. eCollection 2014. Review.

12.

Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing.

Robbez-Masson LJ, Bödör C, Jones JL, Hurst HC, Fitzgibbon J, Hart IR, Grose RP.

PLoS One. 2013 Nov 12;8(11):e78839. doi: 10.1371/journal.pone.0078839. eCollection 2013.

13.

FGFR signalling in women's cancers.

Fearon AE, Gould CR, Grose RP.

Int J Biochem Cell Biol. 2013 Dec;45(12):2832-42. doi: 10.1016/j.biocel.2013.09.017. Epub 2013 Oct 19. Review.

PMID:
24148254

Supplemental Content

Loading ...
Support Center